SCHEMBL1701153

SCHEMBL1701153

CCOCCC(OCC)OCC

nearest known ligand 0.39

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
THRB P10828 1/20 0.38
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31079405 0.92 THRB (0.40) THRBLMNA
SCHEMBL11255584 0.89 ALDH1A1 (0.32) ALDH1A1THRB
SCHEMBL3920740 0.85 ALDH1A1 (0.33) ALDH1A1THRBLMNA
SCHEMBL9252193 0.83 ALDH1A1 (0.43) ALDH1A1TSHR
SCHEMBL11255581 0.82 THRB (0.33) THRBLMNA
Magnesium Chloride Anhydrous SCHEMBL28447292 0.82 THRB (0.33) THRBLMNA
SCHEMBL1608587 0.82
SCHEMBL3103579 0.81 ADRB2 (0.38) THRBLMNA
SCHEMBL13319641 0.80 ALDH1A1 (0.50) ALDH1A1THRBLMNATSHR
SCHEMBL12337817 0.80 TSHR (0.34) ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8734541-B2 Diesel fuel formulation SHELL OIL COMPANY (US) 2014-05-27 US claimed
EP-2585562-A1 DIESEL FUEL FORMULATION Shell Internationale Research Maatschappij B.V. (NL) 2013-05-01 EP claimed
US-20120145106-A1 DIESEL FUEL FORMULATION SHELL OIL COMPANY (US) 2012-06-14 US claimed
WO-2011161032-A1 DIESEL FUEL FORMULATION SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 2011-12-29 WO claimed
US-20050044778-A1 Fuel compositions employing catalyst combustion structure OCTANE INTERNATIONAL, LTD. 2005-03-03 US claimed
EP-0658155-A4 PROCESS FOR CONVERTING ACETALS TO ETHERS. BP CHEM INT LTD (GB) 1996-01-24 EP claimed
EP-0658155-A1 PROCESS FOR CONVERTING ACETALS TO ETHERS BP Chemicals Limited (GB) 1995-06-21 EP claimed
WO-1995001949-A1 PROCESS FOR CONVERTING ACETALS TO ETHERS BP CHEMICALS LIMITED (GB) 1995-01-19 WO claimed
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-09-18 US disclosed
US-20250206691-A1 PROCESS FOR THE RUTHENIUM-CATALYSED HYDROGENATION OF ALDEHYDE ACETALS EVONIK OXENO GMBH & CO. KG (DE) 2025-06-26 US disclosed
CN-120192213-A Process for hydrogenating acetals by ruthenium catalysis 赢创奥克森诺有限责任两合公司 2025-06-24 CN disclosed
US-11407699-B2 Methods of making modified alcohol containing products SPIRITED BEVTECH LLC (US) 2022-08-09 US disclosed
US-11066351-B2 Organic compound, three-dimensional organic framework formed by using organic compound, separation sieve and optical layer, which comprise organic framework, and optical device comprising optical layer as optical amplification layer IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) (KR) 2021-07-20 US disclosed
US-20210198603-A1 ALCOHOLIC BEVERAGES PRODUCED FROM INDIVIDUAL COMPONENTS AVA FOOD LABS, INC. 2021-07-01 US disclosed
EP-0266979-A2 Therapeutic agents IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-05-11 EP disclosed
EP-0201351-A2 1,3-Dioxane ethers IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-11-12 EP disclosed
US-4536585-A Method of making acetals by catalytic reaction of aldehydes with hydroxyalkanes THE STANDARD OIL COMPANY (US) 1985-08-20 US disclosed
US-4239901-A ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1980-12-16 US disclosed
US-4038386-A INOTROPIC AGENTS DEUTSCH GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) 1977-07-26 US disclosed
US-3966768-A Substituted 1,3-dioxepins THE DOW CHEMICAL COMPANY (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066351-B2 Organic compound, three-dimensional organic framework formed by using organic compound, separation sieve and optical layer, which comprise organic framework, and optical device comprising optical layer as optical amplification layer OR10J3, POF1B, ORC3 ALDH1A1 2899/4885THRB 4748/4885LMNA 2924/4885
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS ACHE, BCHE, DDT ALDH1A1 4134/4885THRB 4280/4885LMNA 3388/4885
US-11407699-B2 Methods of making modified alcohol containing products ADH1C, ADH1A, ADH5 ALDH1A1 7/4885THRB 4714/4885LMNA 1829/4885
US-20250206691-A1 PROCESS FOR THE RUTHENIUM-CATALYSED HYDROGENATION OF ALDEHYDE ACETALS ADH5, ALDH2, ADH1A ALDH1A1 7/4885THRB 4589/4885LMNA 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.